2023-05-16 21:04:48 ET
Summary
- On May 15, Oramed announced that their partner in China had completed a positive phase 3 oral insulin trial in China and had submitted an application to the Chinese regulator.
- In the same PR, Oramed announced their post-hoc analysis of their failed US p3 trial and said that they found positive data in subgroups of trial participants.
- Oramed is "exploring ways to move forward with its oral insulin product". Previously, Oramed expected to discontinue its oral insulin clinical activities for T2D [Type2 Diabetics].
- I take a look and share my thoughts here.
For further details see:
Oramed: Buyer Beware